Blog

HYPERA – FATO RELEVANTE

HYPERA S.A. (“Companhia” ou “Hypera Pharma”), em cumprimento à regulamentação em vigor, informa que recebeu nesta data proposta de oferta pública de aquisições de ações e de combinação de negócios da NC Farma Participações S.A., nos termos da proposta anexa (“Proposta”). O Conselho de Administração tomará providências para avaliação diligente da Proposta, incluindo a contratação de assessores externos.

A Companhia comunicará ao mercado em caso de atualizações sobre o tema.

Itaú BBA on Drugstores: HYPE’s WK Shifts – Limited Impacts for Drugstores By Rodrigo Gastim

Hypera has recently announced its intention to temporarily scale back sales efforts in order to recalibrate inventory levels within its distribution channel, which has historically been overstocked. This involves restructuring its working capital, aiming to reduce receivables by ~56 days by the end of 2025. Our HC team has published an in-depth report on the implications for HYPE (link here). In this note, we shift our focus to the impact on the drugstore chains. On balance, minimal practical impacts for RADL, PNVL, and PGMN. The supplier base for these drugstores is highly fragmented, with their top-3 suppliers contributing to less than 10-15% of total COGS, according to our estimates. Given the competitive nature of the market, suppliers face significant challenges in altering commercial terms without risking a loss of market share. While a reduction in receivables for HYPE may translate to shorter payment terms for drugstores, this should be counterbalanced by an improvement in inventory turnover (reduced days), thus maintaining equilibrium. Regarding LT discount structures, the impact appears neutral (typically, shorter payment terms mean higher discounts, while lower inventory levels mean the opposite). For HYPE, we view this as a ‘shift of value’ from the P&L to the cash flow. Although this adjustment may temporarily impact ST discounts for drugstores (due to reduced sales), we anticipate it to be a one-time recalibration, with commercial conditions normalizing once the significant adjustment – likely to affect HYPE’s P&L for a while – has been implemented.

Biomm obtém registro do anticorpo monoclonal Bevyx, para tratamento de câncer, junto à Anvisa

Com a aprovação do registro pela Anvisa, a Biomm solicitará autorização de preço do produto junto à Câmara de Regulação de Mercado de Medicamentos (Cmed)

STF definirá esta semana se cooperativas médicas podem pedir recuperação judicial

Por enquanto, placar do julgamento está empatado em 1 x 1 na Corte

Ações da Hypera (HYPE3) desabam com anúncio de programa de otimização do capital de giro

Goldman Sachs corta preço-alvo dos papéis da companhia de R$ 37 para R$ 31,50 e reiteram recomendação neutra